China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
BASEL, Switzerland and CAMBRIDGE, Mass., April 27, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at the InterContinental Boston Hotel in Boston, MA.
Event: 42nd Annual Deutsche Bank Health Care Conference
Date: Wednesday, May 3rd
Time: 4:10 PM EDT
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected]
